COYA vs. ERAS, VERV, TBPH, LXRX, ESPR, SLRN, FBLG, CTNM, TERN, and BMEA
Should you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include Erasca (ERAS), Verve Therapeutics (VERV), Theravance Biopharma (TBPH), Lexicon Pharmaceuticals (LXRX), Esperion Therapeutics (ESPR), Acelyrin (SLRN), FibroBiologics (FBLG), Contineum Therapeutics (CTNM), Terns Pharmaceuticals (TERN), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical preparations" industry.
Erasca (NASDAQ:ERAS) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends, analyst recommendations and community ranking.
Coya Therapeutics has higher revenue and earnings than Erasca. Coya Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.
Coya Therapeutics' return on equity of -38.83% beat Erasca's return on equity.
Erasca received 10 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 88.89% of users gave Coya Therapeutics an outperform vote while only 64.29% of users gave Erasca an outperform vote.
Erasca currently has a consensus price target of $6.83, suggesting a potential upside of 171.16%. Coya Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 83.73%. Given Coya Therapeutics' higher probable upside, research analysts clearly believe Erasca is more favorable than Coya Therapeutics.
67.8% of Erasca shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 21.5% of Erasca shares are owned by insiders. Comparatively, 12.0% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Erasca has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
In the previous week, Erasca and Erasca both had 5 articles in the media. Erasca's average media sentiment score of 1.29 beat Coya Therapeutics' score of 0.15 indicating that Coya Therapeutics is being referred to more favorably in the news media.
Summary
Erasca beats Coya Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Coya Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coya Therapeutics Competitors List
Related Companies and Tools
